Yan Wei-Hua
Medical Research Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical College, 150 Xi'men Street, Linhai, Zhejiang, People's Republic of China.
Endocr Metab Immune Disord Drug Targets. 2011 Mar;11(1):76-89. doi: 10.2174/187153011794982059.
Human leukocyte antigen G (HLA-G) is a non-classic major histocompatibility complex (MHC) class I molecule that functions as an immune suppressive molecule. HLA-G has direct inhibitory effects on natural killer cells(NK), dendritic cells (DC), T cells and has long-term tolerogenic indirect effects by inducing regulator T cells (Treg). HLA-G has been reported to be involved in various physio-pathological conditions such as reproduction, transplantation, autoimmunity, infectious and malignant diseases. In this context, aberrant expression of HLA-G in malignant diseases including hematological and solid tumors has been extensively investigated and its relevance to clinicoparameters and potential significance in diagnosis, prognosis and immune target therapy has been postulated. We here summarized the HLA-G expression in malignancies and emphasis its clinical relevance to malignant disease diagnosis, prognosis, and its potential in target-based immunotherapy was also discussed.
人类白细胞抗原G(HLA-G)是一种非经典的主要组织相容性复合体(MHC)I类分子,作为一种免疫抑制分子发挥作用。HLA-G对自然杀伤细胞(NK)、树突状细胞(DC)、T细胞具有直接抑制作用,并通过诱导调节性T细胞(Treg)产生长期的致耐受性间接作用。据报道,HLA-G参与了各种生理病理状况,如生殖、移植、自身免疫、感染性疾病和恶性疾病。在此背景下,HLA-G在包括血液系统肿瘤和实体瘤在内的恶性疾病中的异常表达已得到广泛研究,并推测了其与临床参数的相关性以及在诊断、预后和免疫靶向治疗中的潜在意义。我们在此总结了HLA-G在恶性肿瘤中的表达,并强调了其与恶性疾病诊断、预后的临床相关性,还讨论了其在基于靶点的免疫治疗中的潜力。